L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. George Simon, an investigator at the MD Anderson Cancer Center for the Phase I study of L-DOS47 with pemetrexed and carboplatin in first
line treatment of metastatic non-squamous non-small cell lung cancer (LDOS001), will present at the IASLC 18th Annual Targeted Therapies of Lung Cancer Meeting at Santa Monica, California.

Dr. Simon’s presentation will be made on February 24, 2018. The presentation will provide an update on the progress of this clinical study, including those patients that have experienced tumor reduction or a partial response in this study.